ArticleACS omega2025
Identification and Analysis of the Role of Zinc Finger Protein 580 in Ischemeia-Reperfusion Injury through Bioinformatics and Experimental Verification.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemeia-reperfusion (I/R) injury is a severe complication after restoring blood perfusion in acute myocardial infarction treatment, in which vascular endothelial cell dysfunction is considered as the key event to exacerbate myocardial injury. We have previously verified the protective function of ZNF580 in endothelial cells, however, the impact of ZNF580 on I/R injury and its underlying mechanisms have not been explored in depth. The purpose of the present study is to investigate the regulatory role of ZNF580 on myocardial I/R injury and confirm that ZNF580 is a potential therapeutic candidate for I/R injury treatment. The potential mechanism of ZNF580 in I/R injury was determined via bioinformatics. A model of I/R injury in human umbilical vein endothelial cells (HUVECs) was subsequently established to confirm whether ZNF580 protects against I/R injury and whether this protective effect is exerted through the regulation of autophagic flow. Our study identified 459 differentially expressed genes (DEGs) in I/R injury. ZNF580 increased cell viability and gradually restored cell morphology, the cytoplasm was full, the intracellular structure was clear, and the cell space was significantly reduced in HUVECs exposed to I/R injury. Both Western blotting and reverse transcription-polymerase chain reaction (RT-qPCR) were used to detect the levels of different apoptosis-related proteins, it is shown that the ZNF580 significantly increased lysosome-associated membrane protein 2 (LAMP2) and light chain 3 (LC3) expressions, and markedly decreased protein 62 (P62) expression. Moreover, ZNF580 decreased lactate dehydrogenase (LDH) levels in the supernatant and the rate of apoptosis. ZNF580 promoted autophagosome and lysosome fusion and increased autophagic flux, thereby protecting HUVECs from I/R injury. Its protective effect is possibly related to the activation of the adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK) signaling pathway.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.